by MM360 Staff | Jun 1, 2025 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by MM360 Staff | Jun 1, 2025 | Myeloma News
Source: Pharmacy Times articles Frank Qian, MD, MPH, discusses the clinical indications, dosing strategies, and cardiovascular outcomes data for prescription omega-3 fatty acids, including the ongoing debate about EPA vs EPA-DHA formulations and the implications of...
by MM360 Staff | May 31, 2025 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by MM360 Staff | May 31, 2025 | Myeloma News
Source: Pharmacy Times articles GLP-1 receptor agonists, including semaglutide and tirzepatide, significantly reduce cardiometabolic risk factors such as dyslipidemia, type 2 diabetes, metabolic dysfunction-associated steatohepatitis, obstructive sleep apnea, chronic...
by MM360 Staff | May 31, 2025 | Myeloma News
Source: Pharmacy Times articles At the 2025 National Lipid Association (NLA) Scientific Sessions, Marlys L. Koschinsky, PhD, FNLA, discusses the role of Lp(a) in cardiovascular risk and the emerging therapies designed to target and lower Lp(a) levels. Read...
by MM360 Staff | May 31, 2025 | Myeloma News
Source: Pharmacy Times articles Post Content Read More